High output heart failure in group 1 pulmonary hypertension and clinical outcomes [0.03%]
组1肺动脉高压患者的心力衰竭高输出量及其临床预后
Ajay Kumar Jha
Ajay Kumar Jha
Advancing cardiovascular risk stratification in COPD: methodological gains and remaining gaps [0.03%]
慢性阻塞性肺病中心血管风险分层的研究进展与不足：方法学成就与剩余空白
Yasith Samarasinghe,Mohsen Sadatsafavi
Yasith Samarasinghe
Ruling out acute pulmonary embolism with SPECT V/Q: comment on the primary results of the SPECTACULAR non-inferiority trial [0.03%]
SPECT通气/灌注显像在急性肺栓塞排除中的价值——SPECTACULAR非劣效性试验的初步结果述评
Nikolaos Tsaftaridis,Deepa Gopalan,Stefano Barco
Nikolaos Tsaftaridis
Reply: Rethinking the optimal cardiac output in pulmonary arterial hypertension [0.03%]
关于重新考虑肺动脉高压的最佳心排血量的回复文章
Yogesh N V Reddy
Yogesh N V Reddy
COS we can - should we? Core outcome sets and pneumonia [0.03%]
COS我们能做吗？应该做吗？——社区获得性肺炎核心结局指标集的研究与应用
James D Chalmers,Martin Kolb
James D Chalmers
HDL cholesterol and interstitial lung abnormalities: metabolism, ageing, and early pulmonary fibrosis [0.03%]
高密度脂蛋白胆固醇与间质性肺部异常：代谢、衰老和早期肺纤维化
Jonathan A Rose,Rachel K Putman
Jonathan A Rose
Frederico Leon Arrabal Fernandes,Suzana Erico Tanni
Frederico Leon Arrabal Fernandes
Clarifying the GOLD 2026 guidance for initial pharmacological COPD treatment [0.03%]
澄清GOLD 2026指导初期慢性阻塞性肺疾病药物治疗的指导意见
Alvar Agustí,David M G Halpin,Bart Celli et al.
Alvar Agustí et al.
AI-driven CT quantification of mucus plugs to evaluate the effect of inhaled hypertonic saline in children aged 3-6 years with CF: a randomized controlled trial [0.03%]
基于人工智能的CT量化评估吸入高渗盐水在3至6岁囊性纤维化儿童中效果的随机对照试验：评价其黏液栓情况的作用
Yuxin Chen,Rudolfs Latisenko,Stephanie D Davis et al.
Yuxin Chen et al.
Prevention of COPD exacerbations with a mucosal trained immunity-based vaccine (MV130): a randomised phase 3 trial [0.03%]
用于预防COPD急性加重的黏膜训练免疫疫苗（MV130）III期随机临床试验
Luis Puente Maestu,Myriam Calle Rubio,Paola Benedetti et al.
Luis Puente Maestu et al.
Background: Respiratory infections are the primary trigger of acute exacerbations in COPD, yet preventive strategies remain limited. This study aims to evaluate the efficacy and safety of MV130, a sublingual mucosal vacci...